WNT 974

Drug Profile

WNT 974

Alternative Names: LGK-974; NVP-LGK974; WNT-974

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer Array BioPharma; Novartis Oncology
  • Class Antineoplastics; Pyrazines; Pyridines; Small molecules
  • Mechanism of Action PORCN protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Colorectal cancer
  • Phase I Cancer

Most Recent Events

  • 06 Sep 2017 WNT 974 is still in phase I/II trials for Colorectal cancer (Combination therapy, Metastatic disease) in Belgium, Canada, Israel, Italy, Netherlands, Singapore, Spain and USA (PO) (NCT02278133)
  • 23 Jun 2017 Array BioPharma completes a phase I/II trial in Colorectal cancer (Combination therapy, Metastatic disease) in Spain, Singapore, Netherlands, Italy, Israel, Canada, Belgium, Australia and USA (IV) (NCT02278133)
  • 09 Mar 2017 Novartis reinitiates enrolment in a phase I trial for Cancer (Late stage disease) in USA, Spain and the Netherlands (NCT01351103)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top